Stem definition | Drug id | CAS RN |
---|---|---|
2780 | 73-22-3 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
None | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Foetal growth restriction | 64.27 | 31.93 | 15 | 576 | 6612 | 50597921 |
Infantile apnoea | 45.39 | 31.93 | 8 | 583 | 865 | 50603668 |
Selective eating disorder | 39.47 | 31.93 | 8 | 583 | 1824 | 50602709 |
Cerebral haemorrhage | 32.08 | 31.93 | 12 | 579 | 27040 | 50577493 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Genital hypoaesthesia | 39.85 | 33.17 | 6 | 399 | 206 | 29573916 |
Ejaculation failure | 38.59 | 33.17 | 7 | 398 | 760 | 29573362 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bronchial hyperreactivity | 64.81 | 26.30 | 13 | 835 | 2499 | 64495385 |
Breast disorder | 57.38 | 26.30 | 11 | 837 | 1673 | 64496211 |
Genital hypoaesthesia | 41.26 | 26.30 | 6 | 842 | 168 | 64497716 |
Ejaculation failure | 36.88 | 26.30 | 6 | 842 | 355 | 64497529 |
Serotonin syndrome | 26.34 | 26.30 | 12 | 836 | 39270 | 64458614 |
None
Source | Code | Description |
---|---|---|
ATC | N06AX02 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D018687 | Antidepressive Agents, Second-Generation |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D011619 | Psychotropic Drugs |
CHEBI has role | CHEBI:27027 | trace elements |
CHEBI has role | CHEBI:35469 | antidepressants |
CHEBI has role | CHEBI:50733 | Dietary Supplement |
CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
CHEBI has role | CHEBI:75772 | S. cerevisiae metabolites |
CHEBI has role | CHEBI:76924 | plant metabolites |
CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
CHEBI has role | CHEBI:83056 | Daphnia magna metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Classical phenylketonuria | contraindication | 7573000 | |
Depressive disorder | contraindication | 35489007 | |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Schizophrenia | contraindication | 58214004 | DOID:5419 |
Autoimmune disease | contraindication | 85828009 | |
Eosinophilia myalgia syndrome | contraindication | 95416007 | DOID:998 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.23 | acidic |
pKa2 | 13.4 | acidic |
pKa3 | 9.51 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Extracellular calcium-sensing receptor | GPCR | ALLOSTERIC MODULATOR | Kd | 4.40 | IUPHAR | ||||
Myeloperoxidase | Enzyme | IC50 | 5.65 | CHEMBL | |||||
Probable G-protein coupled receptor 139 | GPCR | AGONIST | IC50 | 4.59 | IUPHAR |
ID | Source |
---|---|
4029345 | VUID |
N0000180301 | NUI |
4018677 | VANDF |
4029345 | VANDF |
C0041249 | UMLSCUI |
CHEBI:57719 | CHEBI |
TRP | PDB_CHEM_ID |
CHEMBL54976 | ChEMBL_ID |
DB00150 | DRUGBANK_ID |
D014364 | MESH_DESCRIPTOR_UI |
6305 | PUBCHEM_CID |
6173 | INN_ID |
717 | IUPHAR_LIGAND_ID |
8DUH1N11BX | UNII |
10898 | RXNORM |
12547 | MMSL |
237270 | MMSL |
48867 | MMSL |
NOCODE | MMSL |
d04732 | MMSL |
001438 | NDDF |
108952000 | SNOMEDCT_US |
54821000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
ProcalAmine | HUMAN PRESCRIPTION DRUG LABEL | 22 | 0264-1915 | INJECTION | 0.05 g | INTRAVENOUS | NDA | 24 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.20 g | INTRAVENOUS | NDA | 23 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.20 g | INTRAVENOUS | NDA | 23 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3200 | SOLUTION | 250 mg | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3205 | SOLUTION | 250 mg | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 250 mg | INTRAVENOUS | ANDA | 20 sections |
FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9010 | INJECTION, SOLUTION | 0.15 g | INTRAVENOUS | NDA | 24 sections |
FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9011 | INJECTION, SOLUTION | 0.15 g | INTRAVENOUS | NDA | 24 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9341 | SOLUTION | 0.20 g | INTRAVENOUS | NDA | 23 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9361 | SOLUTION | 0.12 g | INTRAVENOUS | NDA | 23 sections |
HepatAmine | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9371 | INJECTION, SOLUTION | 0.07 g | INTRAVENOUS | NDA | 23 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 144 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION, EMULSION | 144 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 144 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 144 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 108 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 144 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 144 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0210 | INJECTION | 144 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0214 | INJECTION | 144 mg | INTRAVENOUS | NDA | 20 sections |
ProSol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0499 | INJECTION, SOLUTION | 320 mg | INTRAVENOUS | NDA | 21 sections |
Clinisol | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0338-0502 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | ANDA | 18 sections |
Travasol | HUMAN PRESCRIPTION DRUG LABEL | 15 | 0338-0644 | INJECTION | 180 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1089 | INJECTION | 77 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1091 | INJECTION | 77 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1099 | INJECTION | 90 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1101 | INJECTION | 90 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1113 | INJECTION | 77 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1115 | INJECTION | 77 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1123 | INJECTION | 90 mg | INTRAVENOUS | NDA | 20 sections |